drug- and toxin-induced PAH or associated to connective tissues disease, hereditary, Patients with diagnosis of Pulmonary Arterial Hypertension of the following types according to 2022 ERS/ESC guidelines: idiopathic
Conditions
Brief summary
Efficacy outcome: clinical improvement and no clinical worsening.
Detailed description
Safety of the intervention: Serum 25(OH) vitD concentration, Six minute walk text (6MWD), Plasmatic levels of N-terminal pro b-type natriuretic peptide (NT-proBNP), Functional class (WHO/NYAS), Estimated pulmonary systolic pressure (PASP), TAPSE/PASP: the ratio of Tricuspid Annular Plane Systolic Excursion (TAPSE) to Pulmonary Arterial Systolic Pressure (PASP), Serum noggin protein level., Non-invasive risk score (NIRS) (FC,6MWT and NT-proBNP)., Quality of life (emPHasis-10)., Adverse effects.
Interventions
Sponsors
Consorci Mar Parc De Salut De Barcelona
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy outcome: clinical improvement and no clinical worsening. | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety of the intervention: Serum 25(OH) vitD concentration, Six minute walk text (6MWD), Plasmatic levels of N-terminal pro b-type natriuretic peptide (NT-proBNP), Functional class (WHO/NYAS), Estimated pulmonary systolic pressure (PASP), TAPSE/PASP: the ratio of Tricuspid Annular Plane Systolic Excursion (TAPSE) to Pulmonary Arterial Systolic Pressure (PASP), Serum noggin protein level., Non-invasive risk score (NIRS) (FC,6MWT and NT-proBNP)., Quality of life (emPHasis-10)., Adverse effects. | — |
Countries
Spain
Outcome results
None listed